In our current work, we further delineated that ADSC-EVs containing miR-223-3p attenuated the lipid accumulation and liver fibrosis by repressing E2F1, whereby alleviating NAFLD. The gene discussed is E2F1; the disease is metabolic dysfunction-associated steatotic liver disease.